Red Door Wealth Management LLC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 11.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,025 shares of the company’s stock after selling 2,075 shares during the quarter. Red Door Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,327,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Papp L Roy & Associates boosted its stake in Merck & Co., Inc. by 1.2% in the second quarter. Papp L Roy & Associates now owns 10,351 shares of the company’s stock valued at $800,000 after acquiring an additional 126 shares during the last quarter. Ferris Capital LLC raised its position in shares of Merck & Co., Inc. by 2.9% during the 2nd quarter. Ferris Capital LLC now owns 4,539 shares of the company’s stock valued at $351,000 after acquiring an additional 129 shares during the last quarter. Pure Financial Advisors Inc. lifted its stake in shares of Merck & Co., Inc. by 0.7% in the 2nd quarter. Pure Financial Advisors Inc. now owns 19,480 shares of the company’s stock valued at $1,506,000 after purchasing an additional 136 shares during the period. GYL Financial Synergies LLC boosted its position in shares of Merck & Co., Inc. by 3.4% in the 2nd quarter. GYL Financial Synergies LLC now owns 4,091 shares of the company’s stock worth $316,000 after purchasing an additional 136 shares during the last quarter. Finally, Shorepoint Capital Partners LLC boosted its position in shares of Merck & Co., Inc. by 0.4% in the 2nd quarter. Shorepoint Capital Partners LLC now owns 32,586 shares of the company’s stock worth $2,520,000 after purchasing an additional 137 shares during the last quarter. 73.18% of the stock is owned by institutional investors and hedge funds.

In other Merck & Co., Inc. news, insider Sanat Chattopadhyay sold 10,380 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $83.01, for a total value of $861,643.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Robert M. Davis sold 251,273 shares of Merck & Co., Inc. stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $81.03, for a total transaction of $20,360,651.19. Following the completion of the transaction, the chief financial officer now directly owns 422,329 shares of the company’s stock, valued at approximately $34,221,318.87. The disclosure for this sale can be found here. Insiders have sold a total of 280,529 shares of company stock worth $22,761,633 in the last ninety days. Insiders own 0.28% of the company’s stock.

Several equities analysts have weighed in on the company. Royal Bank of Canada reissued a “hold” rating on shares of Merck & Co., Inc. in a research note on Tuesday, August 4th. ValuEngine downgraded shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating in a research report on Thursday, October 1st. SVB Leerink boosted their price objective on shares of Merck & Co., Inc. from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Tuesday, August 25th. Mizuho reiterated a “buy” rating on shares of Merck & Co., Inc. in a report on Tuesday, September 22nd. Finally, Morgan Stanley reissued a “buy” rating and set a $89.00 price target on shares of Merck & Co., Inc. in a research report on Tuesday, June 23rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have issued a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average price target of $95.08.

Shares of MRK stock opened at $79.83 on Friday. Merck & Co., Inc. has a 12 month low of $65.25 and a 12 month high of $92.64. The company’s fifty day simple moving average is $83.27 and its 200-day simple moving average is $80.42. The firm has a market cap of $201.91 billion, a PE ratio of 19.47, a P/E/G ratio of 2.10 and a beta of 0.43. The company has a quick ratio of 1.05, a current ratio of 1.32 and a debt-to-equity ratio of 0.94.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Friday, July 31st. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.14 by $0.23. The firm had revenue of $10.87 billion for the quarter, compared to analysts’ expectations of $10.52 billion. Merck & Co., Inc. had a net margin of 22.20% and a return on equity of 52.94%. The company’s revenue for the quarter was down 7.6% on a year-over-year basis. During the same period in the previous year, the firm posted $1.30 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 5.68 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were paid a $0.61 dividend. The ex-dividend date was Monday, September 14th. This represents a $2.44 dividend on an annualized basis and a yield of 3.06%. Merck & Co., Inc.’s dividend payout ratio is 47.01%.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Read More: What are no-load funds?

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.